New drug duo shows promise against tough prostate cancer
NCT ID NCT03910660
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
This study tested a new oral drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the right dose and see if the combo can shrink tumors or slow the disease. Participants had either small cell neuroendocrine or adenocarcinoma type prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BioXcel Clinical Research Site
Denver, Colorado, 80211, United States
-
BioXcel Clinical Research Site
Detroit, Michigan, 48201, United States
-
BioXcel Clinical Research Site
Glasgow, England, G12 0YN, United Kingdom
-
BioXcel Clinical Research Site
London, Great Britain, W1T 7HA, United Kingdom
-
BioXcel Clinical Research Site
Sutton, Surrey, SM2 5NG, United Kingdom
-
Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute)
Lake Success, New York, 11042, United States
-
Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of California San Francisco (UCSF)
San Francisco, California, 94158, United States
-
Weill Cornell Medicine New York
New York, New York, 10021, United States
-
White Plains Hospital Center for Cancer Care
White Plains, New York, 10601, United States
-
Yale University
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.